IBRX Q4 2020 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21,000-97.7% YoY

Gross Profit

-$2M-10600.0% margin

Operating Income

-$31M-147076.2% margin

Net Income

-$32M-153009.5% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-86.1%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$57M

Stock-Based Comp.

$671,000

Balance Sheet

Total Assets

$221M

Total Liabilities

$340M

Stockholders' Equity

-$120M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21,000	$920,000	-97.7%
Gross Profit	-$2M	$920,000	-342.0%
Operating Income	-$31M	-$21M	-49.9%
Net Income	-$32M	-$22M	-44.2%